This did lead to some softening in recovery trends late in the quarter. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. The format and location will be announced at a later date, but we hope that you're able to join us for this event, where we look forward to sharing the details about our robust pipeline and differentiated capabilities that gives us the confidence in our ability to sustain growth in Pharmaceuticals at above-market levels. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 1.5% worldwide, 2.8% in the U.S., and 0.2% outside the U.S. Net earnings for the full-year 2020 were $14.7 billion and diluted earnings per share was $5.51 versus diluted earnings per share of $5.63 a year ago. Thank you. And I'm just curious. Of course, with 2019 -- or 2020, excuse me, and the effect of COVID, that had a very significant impact. In December, we expanded our retina pipeline by acquiring the rights to Hemera Biosciences' investigational gene therapy, HMR59, a one-time outpatient intravitreal injection to help preserve vision in patients with geographic atrophy, a severe form of age-related macular degeneration where, currently, there are no other approved therapies. Excluding the net impact of acquisitions and divestitures, primarily the divestiture of ASP, adjusted operational sales decline was 1.5% worldwide. Alex Gorsky Well, Chris and Robbie, thank you very much for having us. Moving to the results for the Surgery business. Just one more -- one on the vaccine and then one financial question. Good morning, Larry, and thanks for the question. And expectations that companies can and should help drive positive change in the society are higher than ever. Gartner also awarded Johnson & Johnson the No. Market data powered by FactSet and Web Financial Group. One-time items positively impacted the current quarter by about 200 basis points. Alex Gorsky -- Chairman of the Board of Directors and Chief Executive Officer. Gartner even honored Johnson & Johnson with a No. The product is obviously generating very healthy growth despite increased competition in the psoriasis space. Yes. Expert Timelines Vary. Could you tease that out a little bit as we think about SKU rationalization versus competitive pressures? And then what we did was, as we provided guidance throughout the year, we kind of gave you a range of expected impact by quarter based on what our original guidance would have been at the beginning of the year. Sales also declined in Europe, where some of the strictest restrictions were deployed to curb the increases in COVID-19 cases. A provider prepares to deliver the COVID-19 vaccine to a recipient. Meet the women behind them. I'll address each segment, starting with Pharmaceuticals, where we anticipate another strong year of above-market growth. Joe Wolk -- Executive Vice President and Chief Financial Officer. Worldwide Pharmaceutical sales of $12.3 billion grew 14.6%, enabled by strength in all regions, with U.S. sales increasing by 15.3% and OUS sales increasing by 13.5%. Our total Pulmonary Hypertension portfolio achieved strong growth of 37.4% with OPSUMIT growth of 36.7% and UPTRAVI growth of 44.1%, both driven by market penetration and share growth, as well as a one-time benefit of about 10 points each resulting from the U.S. distributor model change we communicated in Q4 2019. The net benefit from these one-time items is comprised of the benefit of the extra shipping days associated with the 53rd week partially offset by the anticipated inventory contractions in China across our portfolio and in our U.S. contact lens business as communicated last quarter. Thanks, Matt. Before it begins, your doctor will use numbing drops (the same ones routinely used at yearly eye exams) to help ease any potential discomfort from the procedure. Appreciate the question. Medical Devices declined by 900 basis points, driven by COVID-19 impacts on the business, including fixed cost deleveraging associated with sales declines. Their vaulted shape keeps your corneas protected during the treatment, which focuses on the inner eyelids, where the Meibomian glands are located. The procedure is done in just four simple steps: 1. Cost of products sold delevered slightly, primarily driven by COVID-19 period costs and fixed costs impacting the Medical Device business partially offset by favorable enterprise portfolio mix and portfolio mix within the Pharmaceutical business. Dr. West's accomplished healthcare background in addition to her deep strategic leadership experience are strong additions to our board of directors. Great. This means the results could change at any time, and the contemplated impact of COVID-19 on the company's business results and outlook is a best estimate based on the information available as of today's date. in 2017. I encourage you to review our 10-K for further details on specific tax matters. As Alex noted, we remain committed to provide a safe and effective vaccine. You did highlight that in your Phase 1/2 data. The performance of our business 2020 reflects the continued confidence from patients, physicians, customers, and consumers in our life-saving medicines and products. And if approved, it will be the first and only long-acting injectable medication with a twice-yearly dosing regimen. This translated in returning $10.5 billion to investors in 2020, approximately 50% of our free cash flow. We believe the industry is just starting to unlock the full potential and benefits of robotic and digital technologies. Please click below to continue to that site. You will see we have provided our earnings adjusted to exclude intangible amortization expense and special items. Over 30 million Americans suffer from MGD, a major cause of dry eyes. Johnson & Johnson Medical Devices Companies, A 24-Hour Guide to Improving Your Allergy Symptoms, Global Dry Eye Platform Leader, Johnson & Johnson Vision, 5 Things Your Contact Lenses Wish They Could Tell You, Company Group Chairman, Johnson & Johnson Vision and Johnson & Johnson Diabetes Care Companies, COVID-19 Update: Your Latest Questions About Johnson & Johnson's Investigational Vaccine Candidate Answered, The COVID-19 Data Plan: 3 Innovative Ways Johnson & Johnson Is Using Data Science to Fight the Pandemic. Joining me on today's call are Alex Gorsky, chairman of the board of directors and chief executive officer; and Joe Wolk, executive vice president, chief financial officer. We believe that our position overall in the contact lens has continued to strengthen, and we did see improvement as we went quarter to quarter and ended the year. Thanks again for all the work you're doing to combat the pandemic. Thanks, David. She had the mask in her hand. We have seen that in other programs that we run, so we're hopeful that we'll see it here. This month, we received FDA 510(k) clearances for both the ENSEAL X1 curved and straight jaw tissue sealer instruments, which will further strengthen our portfolio of advanced energy devices. And hence, will we have any insight in terms of the vaccine efficacy against some of these new variants? Curious to learn more about how it works? ), Anyone can get MGD, but some of us are more prone to it than others. Thank you. But obviously, there's a lot of moving parts. Anyone can get MGD, but some of us are more prone than others. In 2020, we filed submissions in the U.S. and EU for paliperidone palmitate 6-month formulation for the treatment of adults diagnosed with schizophrenia. While MGD has traditionally been hard to treat, there’s a breakthrough therapy that’s making it far simpler to do: the LipiFlow® Thermal Pulsation System, which uses a cutting-edge device to heat up and massage away the blockage in just 12 minutes, right in your eye doctor’s office. And we're confident that here too is a market that we think is very -- has very low penetration, less than 5% or 10%, certainly on a global basis, more so in certain categories here in the United States. Stock Advisor launched in February of 2002. It is a competitive category. Appreciate the questions. Postmenopausal women are also at higher risk for MGD. Thank you. I will now turn the call over to Alex to share our overall results and business highlights. But we look forward to launching that over the course of 2021 and again, expanding our overall position. From a macroeconomic perspective, our outlook assumes stabilizing employment levels and a reduction in social restrictions as the year progresses.

Houston's Menu Peachtree, Les Misérables Summary, Sublime Album Covers, Energy Vault Valuation, Next For Autism Board, Sudarshan Kriya Everyday, Blue Thunbergia Seeds, Samsung Fast Charger 45w, Manuel Paolo Villar Iii, Pbr Whiskey Total Wine, Samsung Reminder On Pc,